Skip to main content
Signal8

eFFECTOR Therapeutics, Inc. (EFTR)

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.

Sector: Biotechnology

Industry: Biotechnology

eFFECTOR Therapeutics, Inc. logo

eFFECTOR Therapeutics, Inc.

OTC:EFTRHealthcare
$0.0002
CLOSED
Mkt Cap$941
EV-
Float4.67M
O/S4.71M
VOL712 sh
$ Vol$0
RVOL1.86×
Inst Own-
SI0.1%
Net Cash/Sh-
EarningsNov 17 · Today
Dilution
eFFECTOR Therapeutics, Inc. logoOTC:EFTRClosed$0.0002
Financials Summary
Revenue$0
Net Income-$35.81M
Total Assets$20.54M
Free Cash Flow-$29.65M
Debt & Equity
Debt 139%
Total Debt$20.55M
Total Equity-$5.79M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
  1. 1:25Reverse split
    Jan 12, 202425 shares → 1
Balance Sheet Details
Assets$20.54M
Liabilities$26.34M
Accounts Receivable$52K
Accounts Payable$2.33M
Inventory$0
PP&E (Net)$193K
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$0$3.55M$1.43M$42M$0
YoY Growth-148.5%-96.6%--
Cost of Revenue$111K$53K$24K$0$307K
Gross Profit-$111K$3.5M$1.41M$42M-$307K
Gross Margin-98.5%98.3%100.0%-
Research and Development$22.92M$23.31M$19.96M$21.83M$23.58M
Selling, General, and Administrative$10.93M$12.64M$13.37M$4.35M$4.71M
Other$0-$53K-$24K$0$0
Total Operating Expenses$33.84M$35.9M$33.3M$26.18M$28.3M
Operating Income (EBIT)-$33.84M-$32.4M-$33.33M$15.82M-$28.61M
Operating Margin--912.0%-2330.6%37.7%-
Interest Expense$2.92M$2.25M$1.76M$1.33M$1.38M
Interest Income$1.95M$439K$6K$67K$239K
Other Income (Expense)-$1.97M$9.74M$47.7M-$1.26M-$1.13M
Income Before Tax (EBT)-$35.81M-$22.66M$15.8M$14.56M-$29.74M
Income Tax Expense$0-$9.74M$0$351K$0
Net Income-$35.81M-$12.93M$15.8M$14.21M-$29.74M
Net Income Margin--363.8%1104.8%33.8%-
Supplementary Data
EPS-16.37-7.859.780.28-539.08
Diluted EPS-16.37-7.859.780.10-539.08
Weighted Average OS2.19M1.65M1.62M598,55955,166
EBITDA-$32.78M-$20.36M$17.59M$16.05M-$28.05M
EBITDA Margin--573.1%1229.8%38.2%-
Balance Sheet
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-31
Assets
Current Assets
Cash and Cash Equivalents$14.88M$8.71M$49.7M$15.22M$3.43M
Short-Term Investments$3.5M$17.6M$0$0$0
Cash and Short-Term Investments$18.37M$26.31M$49.7M$15.22M$3.43M
Accounts Receivable$52K$27K$100K$0$0
Inventory$0-$27K-$100K$0$0
Other Current Assets$1.42M$1.7M$3.09M$0$845K
Total Current Assets$19.84M$28.01M$52.9M$16.58M$4.27M
Long-Term Assets
Property, Plant & Equipment Net$193K$352K$257K$126K$823K
Goodwill$0$0$0$0$0
Intangible Assets$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Deferred Tax Assets$0$0$0$0$0
Other Long-Term Assets$513K$711K$903K$0$0
Total Long-Term Assets$706K$1.06M$1.16M$126K$823K
Other Assets$0$0$0$0$0
Total Assets$20.54M$29.08M$54.06M$16.7M$5.09M
Liabilities
Current Liabilities
Accounts Payable$2.33M$1.49M$516K$347K$598K
Short-Term Debt$20.48M$20.16M$0$5.91M$15.24M
Current Income Tax Payable$0$463K$351K$351K$0
Current Unearned Revenue$0$0$0$1.98M$0
Other Current Liabilities$1.59M$1.39M$1.34M-$148K$3.09M
Total Current Liabilities$25.8M$25.07M$3.98M$8.78M$18.93M
Long-Term Liabilities
Long-Term Debt$0$60K$19.86M$6.95M$0
Long-Term Unearned Revenue$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0
Other Long-Term Liabilities$543K$46K$12.81M$133.22M$0
Total Long-Term Liabilities$543K$106K$32.79M$140.17M$0
Other Liabilities$0$0$0$0$0
Total Liabilities$26.34M$25.18M$36.77M$148.95M$18.93M
Stockholders' Equity
Preferred Stock$0$0$0$133.22M$133.22M
Common Stock$0$4K$4K$454$1K
Retained Earnings-$179.38M-$143.57M-$120.9M-$136.7M-$150.91M
Comprehensive Income & Other$0-$18K-$0$0-$999
Other Stockholders' Equity$173.58M$147.46M$138.18M$137.68M$137.07M
Total Equity-$5.79M$3.9M$17.28M$979K-$13.84M
Minority Interest$0$0$0$0$0
Total Liabilities and Equity$20.54M$29.08M$54.06M$149.93M$5.09M
Supplementary Data
Total Debt$20.55M$20.28M$20.03M$12.96M$15.24M
Net Debt$5.67M$11.57M-$29.67M-$2.25M$11.82M
Cash Flow Statement
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-31
Operating Activities
Net Income-$35.81M-$22.66M$15.8M$14.21M-$29.74M
Depreciation & Amortization$111K$53K$24K$160K$307K
Deferred Income Tax$0$0-$539K-$333K-$1.99M
Stock-Based Compensation$4.59M$5.33M$8.66M$499K$646K
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$0
  Inventory$0$0$0$0$0
  Accounts Payable$855K$958K$155K-$251K-$727K
  Other Working Capital$830K$1.72M-$393K-$573K$1.8M
Total Working Capital Change$1.69M$2.68M-$238K-$824K$1.07M
Other Non-Cash Items-$130K-$11.3M-$48.59M$122K$2.1M
Net Cash from Operating-$29.55M-$25.9M-$24.89M$13.84M-$27.6M
Investing Activities
Capital Expenditures-$97K-$192K-$42K-$154K-$4K
Acquisitions$0$17.67M$607K$0$88K
Purchases of Investments-$17.17M-$52.42M$0$0$0
Sales of Investments$31.75M$34.75M$0$0$0
Other Investing Activities$0-$17.67M$0$0$0
Net Cash from Investing$14.48M-$17.86M$565K-$154K$84K
Financing Activities
Debt Repaid---$5.89M$2M-
Common Stock Issuance$21.18M$2.8M$56K$108K$20.33M
Common Stock Repurchases$0$0$0$0-$86K
Dividends Paid$0$0$0$0$0
Other Financing Activities$56K-$34K$52.86M$0$20.24M
Net Cash from Financing$21.23M$2.77M$58.81M-$1.89M$20.24M
Forex Effect$0$0$0$0$10.7M
Net Change in Cash$6.17M-$40.99M$34.49M$11.79M$3.43M
Supplementary Data
Operating Cash Flow-$29.55M-$25.9M-$24.89M$13.84M-$27.6M
Capital Expenditure-$97K-$192K-$42K-$154K-$4K
Free Cash Flow-$29.65M-$26.09M-$24.93M$13.68M-$27.6M
Cash at Beginning$8.71M$49.7M$15.22M$3.43M$0
Cash at End$14.88M$8.71M$49.7M$15.22M$3.43M